Yuji Oshikawa‐Kumade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuji Oshikawa‐Kumade has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Miyagi Maeshima
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
1 shared publication Chitose Ogawa
Department of Pediatric Oncology National Cancer Center Hospital Tokyo Japan
1 shared publicationHirokazu Kariyazono
Division of Molecular Oncology National Cancer Center Research Institute Tokyo Japan
1 shared publication- Hiromichi Matsushita
Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
1 shared publication - Hiroyuki Mano
Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
1 shared publication - Junji Koya
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 17 June 2022
- Published by Wiley in Cancer Science
- Vol. 113 (8) , 2763-2777
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
Identification of genetic alterations through next‐generation sequencing (NGS) can guide treatment decision‐making by providing information on diagnosis, therapy selection, and prognostic stratification in patients with hematological malignancies. Although the utility of NGS‐based genomic profiling assays was investigated in hematological malignancies, no assays sufficiently cover driver mutations, including recently discovered ones, as well as fusions and/or pathogenic germline variants. To address these issues, here we have devised an integrated DNA/RNA profiling assay to detect various types of somatic alterations and germline variants at once. Particularly, our assay can successfully identify copy number alterations and structural variations, including immunoglobulin heavy chain translocations, IKZF1 intragenic deletions, and rare fusions. Using this assay, we conducted a prospective study to investigate the feasibility and clinical usefulness of comprehensive genomic profiling for 452 recurrently altered genes in hematological malignancies. In total, 176 patients (with 188 specimens) were analyzed, in which at least one alteration was detected in 171 (97%) patients, with a median number of total alterations of 7 (0–55). Among them, 145 (82%), 86 (49%), and 102 (58%) patients harbored at least one clinically relevant alteration for diagnosis, treatment, and prognosis, respectively. The proportion of patients with clinically relevant alterations was the highest in acute myeloid leukemia, whereas this assay was less informative in T/natural killer‐cell lymphoma. These results suggest the clinical utility of NGS‐based genomic profiling, particularly for their diagnosis and prognostic prediction, thereby highlighting the promise of precision medicine in hematological malignancies.
- 17 June 2022
- Published by Wiley in Cancer Science
- Vol. 113 (8) , 2763-2777
Open AccessFeasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
Identification of genetic alterations through next‐generation sequencing (NGS) can guide treatment decision‐making by providing information on diagnosis, therapy selection, and prognostic stratification in patients with hematological malignancies. Although the utility of NGS‐based genomic profiling assays was investigated in hematological malignancies, no assays sufficiently cover driver mutations, including recently discovered ones, as well as fusions and/or pathogenic germline variants. To address these issues, here we have devised an integrated DNA/RNA profiling assay to detect various types of somatic alterations and germline variants at once. Particularly, our assay can successfully identify copy number alterations and structural variations, including immunoglobulin heavy chain translocations, IKZF1 intragenic deletions, and rare fusions. Using this assay, we conducted a prospective study to investigate the feasibility and clinical usefulness of comprehensive genomic profiling for 452 recurrently altered genes in hematological malignancies. In total, 176 patients (with 188 specimens) were analyzed, in which at least one alteration was detected in 171 (97%) patients, with a median number of total alterations of 7 (0–55). Among them, 145 (82%), 86 (49%), and 102 (58%) patients harbored at least one clinically relevant alteration for diagnosis, treatment, and prognosis, respectively. The proportion of patients with clinically relevant alterations was the highest in acute myeloid leukemia, whereas this assay was less informative in T/natural killer‐cell lymphoma. These results suggest the clinical utility of NGS‐based genomic profiling, particularly for their diagnosis and prognostic prediction, thereby highlighting the promise of precision medicine in hematological malignancies.